PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

NCT00544674 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated early due to discovery of new mechanism of activation.

Conditions

Lung Cancer

Interventions

DRUG: PR104
OTHER: F-18-fluoromisonidazole

Sponsor

Proacta, Incorporated